CHRS Q3 2020 Earnings — Coherus Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CHRSCoherus Oncology, Inc.

$219M

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$114M+1.7% YoY

Gross Profit

$105M92.1% margin

Operating Income

$34M29.7% margin

Net Income

$28M24.6% margin

EPS (Diluted)

$0.33

QoQ Revenue Growth

-16.3%

Cash Flow

Operating Cash Flow

$47M

Free Cash Flow

$45M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$804M

Total Liabilities

$548M

Stockholders' Equity

$256M

Cash & Equivalents

$292M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$114M	$112M	+1.7%
Gross Profit	$105M	$105M	-0.7%
Operating Income	$34M	$52M	-35.0%
Net Income	$28M	$47M	-40.6%